Eduardo Esteban-Zubero1* and Cristina García-Muro2
1Emergency Department, Hospital San Pedro, Logroño, Spain
2Department of Pediatrics, Hospital San Pedro, Logroño, Spain
*Corresponding Author: Eduardo Esteban-Zubero, Emergency Department, Hospital San Pedro, Logroño, Spain.
Received: August 19, 2020; Published: August 31, 2020
Keywords: suPAR; Biomarkers; COVID-19; Pandemic
suPAR: Soluble Urokinase-Type Plasminogen Activator Receptor; ED: Emergency Department; ALI: Acute Lung Injury; ARDS: Acute Respiratory Distress Syndrome; COPD: Chronic Obstructive Pulmonary Disease
The biomarker suPAR (soluble urokinase-type plasminogen activator receptor), discovered in 1992, is the soluble form of the cell membrane-bound protein uPAR, which is expressed primarily in immune cells, endothelial cells and smooth muscle cells. uPAR is released in inflammatory or activation processes of the immune system, therefore, in these situations, suPAR reflects the degree of immune activation in the subject .
Citation: Eduardo Esteban-Zubero and Cristina García-Muro. “Biomarkers in the Prognosis of COVID-19 in the Emergency Department: May the Soluble Urokinase Plasminogen Activator Receptor (suPAR) Help?”. Acta Scientific Clinical Case Reports 1.10 (2020): 01-03.
Copyright: © 2020 Eduardo Esteban-Zubero and Cristina García-Muro. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.